Exact Sciences (EXAS) Explodes 17%: Abbott Buyout Shock — The Market Woke Up!

@WallStreetPulse01

Exact Sciences (EXAS) Explodes 17%: Abbott Buyout Shock — The Market Woke Up!

Exact Sciences Corp (EXAS) just detonated on the charts — jumping to $101.42, a violent +17.69% move that stunned Wall Street and triggered one of the most aggressive single-day repricing events in the entire healthcare sector.

This is NOT a normal earnings pop.
This is NOT simple momentum.
This is the market reacting to a potential Abbott Laboratories takeover, a deal that would instantly transform Exact Sciences from a growth-struggling diagnostics company into one of the most valuable strategic assets in the entire U.S. medical ecosystem.

🔥 Why EXAS Is Exploding Today

• Abbott is rumored to be preparing a major buyout
• EXAS’ Cologuard franchise has unmatched brand dominance
• Massive database of cancer-screening data = gold in the AI era
• Short sellers are trapped and forced to cover
• Hedge funds entering merger-arbitrage positions
• Multi-million share volume shows complete investor rotation

This is not a rally — it’s a repricing.

🧠 Why Abbott Wants Exact Sciences

Abbott isn’t paying for a stool test…
They’re paying for:

• A national diagnostics infrastructure
• A brand doctors already trust
• Millions of biological samples
• A pipeline of multi-cancer detection tools
• A moat that competitors haven’t been able to crack

This deal would catapult Abbott into the early-cancer-screening market overnight.

#ExactSciences #EXAS #Abbott #MergerNews #BiotechStocks #HealthcareStocks
#StockMarketNews #TakeoverDeal #Investing #USStocks #BigMovers #DiagnosticsMarket
#HealthcareInnovation #FidelityInvest #SoFiInvest #RobinhoodStocks #CancerScreening
#WallStreetNews #MarketAnalysis #BiotechBreakout

Exact Sciences, EXAS stock, EXAS analysis, EXAS price today, Abbott takeover EXAS, Abbott acquisition rumor, EXAS buyout, Exact Sciences news, biotech stock breakout, healthcare merger news, diagnostics stocks, cancer screening market, Cologuard test analysis, FDA diagnostics companies, Abbott Labs news, EXAS stock forecast, biotech takeover targets, healthcare investing 2025, US diagnostics market, medical testing stocks, merger arbitrage stocks, M&A news, EXAS premarket news, Robinhood stocks today, SoFi Invest stocks, fidelity brokerage stock list, healthcare sector breakout, oncology diagnostics stocks, multi-cancer detection companies, biotechnology explosive stocks, FDA approval stocks, diagnostic innovation trends, precision medicine stocks, cancer screening AI, healthcare data companies, EXAS squeeze, EXAS price jump, medical infrastructure stocks, Abbott strategic acquisition, EXAS merger valuation, takeover premium stocks, high-volume stock movers, Wall Street big movers, M&A speculation stocks, healthcare sector rotation, biotech institutional buying, Exact Sciences long term, diagnostics pipeline value, EXAS new support level, cancer testing revenue, early detection market, screening test demand, oncology market growth, AI in diagnostics, healthcare valuation reset, biotech premium expansion, EXAS deal risks, FTC merger review, healthcare consolidation trend, stock short squeeze 2025, high-volatility stocks USA, merger arbitrage opportunity, takeover offer stocks, life sciences companies, healthcare mega mergers, diagnostic labs acquisition, US healthcare revolution, Exact Sciences data advantage, Exact Sciences pipeline, EXAS chart breakout, revenue growth EXAS, medical research stocks, cancer biology stocks, precision diagnostics leaders, medical innovation companies, cancer screening technology, healthcare M&A boom, biotech valuations 2025, EXAS abnormal volume, hedge fund buying EXAS, institutional rotation into healthcare, US medical stocks, dealing with merger news, EXAS technical levels, EXAS trading strategy, Exact Sciences investment thesis.